Clinical-stage company developing a new generation of adoptive cell therapies for cancers, with a focus on addressing primary mechanisms of resistance to CAR-T therapies.
Red Tree Board Member
Heath Lukatch, Ph.D.
Affiliated with Red Tree SAB Member